Admission risk factors for cerebral vasospasm in ruptured brain arteriovenous malformations: An observational study by Chhor, Vibol et al.
RESEARCH Open Access
Admission risk factors for cerebral vasospasm in
ruptured brain arteriovenous malformations: An
observational study
Vibol Chhor
1, Yannick Le Manach
1,2, Fréderic Clarençon
3, Aurélien Nouet
4, Jean-Louis Daban
1, Lamine Abdennour
1
, Louis Puybasset
1 and Thomas Lescot
1*
Abstract
Introduction: Cerebral vasospasm is a well-documented complication of aneurismal subarachnoid hemorrhage but
has not been extensively studied in brain arteriovenous malformations (BAVMs). Here, our purpose was to identify
risk factors for cerebral vasospasm after BAVM rupture in patients requiring intensive care unit (ICU) admission.
Methods: Patients admitted to our ICU from January 2003 to May 2010 for BAVM rupture were included in this
observational study. Clinical, laboratory and radiological features from admission to ICU discharge were recorded.
The primary endpoint was cerebral vasospasm by transcranial Doppler (TCD-VS) or cerebral infarction (CI)
associated with vasospasm. Secondary endpoints included the Glasgow Outcome Scale (GOS) at ICU discharge.
Results: Of 2,734 patients admitted to our ICU during the study period, 72 (2.6%) with ruptured BAVM were
included. TCD-VS occurred in 12 (17%) and CI in 6 (8%) patients. All patients with CI had a previous diagnosis of
TCD-VS. A Glasgow Coma Scale score <8 was a risk factor for both TCD-VS (relative risk (RR), 4.7; 95% confidence
interval (95% CI), 1.6 to 26) and CI (RR, 7.8; 95% CI, 0.1 to 63). Independent risk factors for TCD-VS by multivariate
analysis were lower Glasgow Coma Scale score (odds ratio (OR) per unit decrease, 1.38; 95% CI, 1.13 to 1.80),
female gender (OR, 4.86; 95% CI, 1.09 to 25.85), and younger age (OR per decade decrease, 1.39; 95% CI, 1.05 to
1.82). The risk of a poor outcome (GOS <4) at ICU discharge was non-significantly increased in the patients with
TCD-VS (RR, 4.9; 95% CI, 0.7 to 35; P = 0.09). All six patients with CI had poor outcomes.
Conclusions: This is the first cohort study describing the incidence and risk factors for cerebral vasospasm after
BAVM rupture. Larger studies are needed to investigate the significance of TCD-vasospasm and CI in these patients.
Introduction
Cerebral vasospasm has been extensively studied follow-
ing aneurismal subarachnoid hemorrhage (SAH) and
has also been reported after traumatic brain injury [1]
or neurosurgery [2]. After aneurismal SAH, several risk
factors present at admission have been identified, such
as younger age, cigarette smoking, poor clinical grade,
arterial hypertension, intracerebral hemorrhage, and
thick cisternal clot [3-5].
Although rupture of a brain arteriovenous malforma-
tion (BAVM) is a cause of SAH, few data are available
on the incidence of cerebral vasospasm after BAVM
rupture. In a series of 100 patients admitted between
1957 and 1977, Parkinson et al. [6] found a single case
of symptomatic vasospasm. In recent years, however,
transcranial Doppler (TCD) and CT/MRI cerebral
angiography have contributed to improve the detection
of vasospasm. Severe vasospasm associated with delayed
cerebral infarction (CI) was reported recently in young
adults [7-11] and children [10,12,13] with BAVM rup-
ture. Medical treatments may be effective in minimizing
the adverse consequences of vasospasm and improving
outcomes after aneurismal SAH [14]. These treatments
may also be effective in ruptured BAVM. Early vasos-
pasm detection in patients with ruptured BAVM would
allow evaluations of therapeutic interventions such as
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identification of risk factors for vasospasm would be
expected to assist in early vasospasm detection.
Here, our aim was to identify risk factors for cerebral
vasospasm present at admission to the intensive care
unit (ICU) for intracerebral bleeding following BAVM
rupture.
Materials and methods
This observational study was conducted in compliance
with STROBE (Strengthening the Reporting of Observa-
tional Studies in Epidemiology) guidelines [15], with the
slight adjustments detailed below.
Patients
Consecutive patients admitted to our 25-bed neurosur-
gical ICU with ruptured BAVM from January 2003 to
May 2010 were eligible. BAVM rupture was defined as
SAH, intraventricular hemorrhage (IVH), or intracereb-
ral hematoma visualized on the admission computed
tomography (CT) scan with concomitant BAVM visuali-
zation by digital subtraction angiography (DSA) or CT-
angiography. Exclusion criteria were admission more
than four days after BAVM rupture suggesting subopti-
mal initial care, death within four days after BAVM rup-
ture (minimal time to vasospasm), BAVM rupture after
elective treatment, and age younger than 15 years. For
this single-center retrospective observational study using
anonymized information, informed consent was waived
by our local ethics review board (Comité de Protection
des Personnes - Ile de France VI Pitié-Salpêtrière) and
according to the French law (Act n°78-17 of 6 January
1978 on data processing, data files, and individual
liberties).
Clinical management
The timing and type of treatment (embolization, surgical
resection, or both) were decided by consensus between
the neurosurgeon and interventional neuroradiologist
based on the clinical presentation and on the location,
size, and angioarchitecture of the BAVM. All patients
were admitted to the ICU. None received prophylactic
nimodipine or statin therapy. A central venous line and
an arterial catheter were inserted when required. Intra-
venous isotonic saline was given routinely to maintain
normovolemia. After the BAVM was secured, systolic
arterial blood pressure was maintained above 130 to 140
mmHg, if needed by continuously infusing norepinephr-
ine. Intracranial pressure (ICP) elevation was treated by
cerebrospinal fluid drainage, mechanical ventilation,
reinforced sedation, and, rarely, moderate hypothermia.
CT was performed regularly during the ICU stay, routi-
nely on the day of transfer from the ICU to the ward,
and in the event of clinical deterioration, to look for
secondary complications such as hydrocephalus, re-
bleeding, or ischemia. Patients diagnosed with TCD
vasospasm (TCD-VS) were treated with continuous
intravenous nimodipine (2 mg/h) and, if the BAVM was
secured, continuous norepinephrine infusion for arterial
blood pressure elevation. DSA was performed in trans-
portable patients. Selective intraarterial chemical vasodi-
lation (nimodipine) and transarterial balloon dilation
were considered to be second-line treatments in patients
with secured BAVMs.
Study variables
At admission, we recorded factors describing the popu-
lation and factors potentially associated with outcomes,
including age, gender, smoking history, arterial hyper-
tension, diabetes, and Glasgow Coma Scale (GCS) score.
The consequences of BAVM rupture identified on
the admission cerebral CT scan were recorded as
intraventricular hemorrhage, intracerebral hematoma,
and/or SAH. SAH was classified as diffuse (diffuse
deposition or thin layer of blood <1 mm), focal (loca-
lized clot >1 mm), or absent. A neuroradiologist (FC)
examined the DSA images to determine the BAVM
angioarchitectural features including location; size;
venous drainage pattern; and presence of a Willis,
intranidal, or feeding-vessel aneurism. The Spetzler-
Martin grade [16] based on nidus size, venous drainage
pattern, and neurological eloquence of adjacent brain
(from 1 to 5, with a higher grade indicating a higher
risk of surgical complication) was also recorded.
BAVM treatments such as surgical BAVM resection,
embolization (microcatheter arterial occlusion using
occlusive materials), or both were recorded. Patients
with incomplete BAVM treatment were identified.
Early BAVM treatment was defined as treatment
started within the first seven days after hospital admis-
sion. Intracranial hypertension was defined as ICP
greater than 20 mmHg for more than 10 minutes.
Endpoints
The primary endpoint was vasospasm in the ICU, with
vasospasm defined as either TCD-VS or CI. Transcranial
color-coded Doppler sonography (Envisor, Philips Medi-
cal Systems, Bothell, WA, USA) was performed daily by
a neurointensivist in unconscious patients and in awake
patients with symptoms (deteriorating consciousness,
focal deficit, headache, fever, confusion) as part of the
routine screening protocol used in our ICU. TCD-VS
was defined as blood flow velocity >120 cm/s in any cer-
ebral vessel [4,17,18]. Velocities were measured at a dis-
tance from the BAVM visualized by color-coded
sonography, and the Aaslid index was determined to
exclude a hyperemia-induced velocity increase [19]. Cer-
ebral infarction was defined as CT or MRI evidence of
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other identifiable cause [20].
The Glasgow Outcome Scale (GOS) at ICU discharge
was among the secondary endpoints. We considered
two categories: poor outcome (death (GOS = 1), vegeta-
tive state (GOS = 2) or severe disability (GOS = 3)), and
good outcome (moderate disability (GOS = 4) or good
recovery (GOS = 5)). Length of stay was the time from
admission to discharge in survivors. Finally, to take early
deaths into account, we recorded ICU-free days as the
number of days spent outside the ICU within the first
40 days; patients who died at any time were classified as
having no ICU-free days.
Statistical analyses
Data are expressed as mean with standard deviation for
normal quantitative variables, median with the inter-
quartile range (IQR) for non-normal quantitative vari-
ables, and numbers (percentages) for qualitative
variables. Normality was assessed using the D’Agostino-
Pearson omnibus test. The unpaired Student’s t test was
used to compare means, the Mann-Whitney U test to
compare medians, and Fisher’s exact method to com-
pare proportions.
Stepwise logistic regression was performed to identify
risk factors for TCD-VS. We used a semi-parsimonious
approach, including only the available unbiased vari-
ables (Table 1). Discrimination of the final models was
assessed using the c-statistic and calibration using the
Hosmer-Lemeshow statistic. Internal validation was
performed using 10-fold cross-validation [21] and was
described based on the difference (optimism) between
the c-statistic in the overall population and cross-vali-
dation samples and on the optimism-corrected c-statis-
tic. The number of patients with CI was too small for
a separate multivariate analysis of risk factors for this
event. P-values were two-tailed and P-values less than
0.05 were considered significant. Statistical analysis
was performed using R software and specific packages
[22].
Results
Cohort description
Figure 1 shows the patient flowchart. During the seven-
year study period, 2,734 patients were admitted to our
neurosurgical ICU including 81 (3.0%) with BAVM rup-
ture. Of these 81 patients, 9 were excluded, for the fol-
lowing reasons: BAVM rupture during elective
treatment (n = 4), death before Day 4 (n = 4), or admis-
sion more than four days after BAVM rupture (n = 1).
This left 72 patients for the study.
Of the 72 study patients, 12 (17%) had TCD-VS and 6
(8%) had CI. DSA was performed in 4 of the 12 TCD-
V Sp a t i e n t sa n ds h o w e dd i f f u s ev a s o s p a s mi na l lo f
them. Figure 2 shows an example of BAVM and angio-
graphic cerebral vasospasm associated with CI.
Median time from BAVM rupture to TCD-VS diagno-
sis was nine days (IQR, 4 to 11). Figure 3 reports the
cumulative incidence of TCD-VS according to time
from BAVM rupture to TCD-VS diagnosis. All patients
with CI had a previous diagnosis of TCD-VS.
Admission risk factors for vasospasm
Table 1 lists the admission features and ICU outcomes
of patients diagnosed with TCD-VS and CI. The risk of
developing TCD-VS was greater in young patients (P =
0.05) and in patients with GCS scores <8 (P <0 . 0 1 ) .
Neither TCD-VS nor CI was significantly associated
with the amount of subarachnoid blood, intraventricular
hemorrhage, or intracerebral hematoma. SAH was diag-
nosed in 32 (44%) of the 72 study patients, including 7
(58%) of the 12 patients with TCD-VS and 3 (50%) of
the 6 patients with CI. IVH was present in 54% of the
patients. More specifically, isolated IVH was diagnosed
i n7o ft h e7 2p a t i e n t s ,i n c l u d i n g6o ft h e6 0p a t i e n t s
without vasospasm and 1 patient with TCD-VS and CI.
Neither TCD-VS nor CI was associated with BAVM
location, angioarchitectural features or treatment modal-
ities. The risk of developing CI was greater in patients
with GCS scores <8 (P = 0.03). Details on the clinical
and radiological features and treatment of each patient
with cerebral vasospasm are given in Table 2.
By multivariate analysis, three factors were associated
with TCD-VS, namely, a worse GCS score, female gen-
der, and younger age (Table 3). The final model had
good discrimination (c-statistic = 0.82) and calibration
(Hosmer-Lemeshow statistic P-value = 0.16). The inter-
nal validation procedure showed good robustness of the
final model (optimism = 0.04).
Consequences of cerebral vasospasm
Patients with TCD-VS had significantly fewer ICU-free
days. Of the 72 study patients, 50 had poor outcomes
(GOS 1, 2 or 3) at ICU discharge. The poor outcome
was directly ascribable to the initial bleed in 42 patients,
to CI in 6 patients, and to re-bleeding in 2 patients. The
risk of a poor outcome was non-significantly increased
in the patients who developed TCD-VS (relative risk,
RR, 4.9; 95% confidence interval 95% CI, 0.7 to 35; P =
0.09). All six patients with CI had poor outcomes. In
the patients without vasospasm, ICU mortality was 17%
and causes of death were as follows: initial bleed (n =
5), refractory intracranial hypertension (n = 3), and re-
bleeding (n = 2). Of the patients with TCD-VS, 42%
died and death was considered directly related to CI in
two patients, intracranial hypertension in two patients,
and the initial bleed in one patient (Table 2). Using
logistic regression including age, GSC, TCD and CI, the
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Page 3 of 10Table 1 Associations linking transcranial Doppler vasospasm and cerebral infarction to admission characteristics and
outcomes
All Patients N = 72 TCD-VS N = 12 CI N = 6
N (%) RR (95% CI) P N (%) RR (95% CI) P
Demographics and medical history
Age (years) 40 +/- 9 33 +/-10 - 0.05 38 +/- 13 - 0.98
Female sex 29 (40%) 7 (58%) 2.1 (0.7 to 5.9) 0.20 4 (67%) 2.9 (0.6 to 15.1) 0.22
Smokers 18 (25%) 1 (8%) 0.3 (0.03 to 2.0) 0.27 1 (17%) 0.6 (0.07 to 4.8) 0.99
Hypertension 8 (11%) 0 (0%) - 0.34 0 (0%) - 0.99
Diabetes 2 (3%) 0 (0%) - 0.99 0 (0%) - 0.99
Admission features
GCS score <8 28 (39%) 9 (75%) 4.7 (1.6 to 26) 0.001 5 (83%) 7.8 (0.1 to 63) 0.03
Seizure 9 13%) 2 (17%) 1.4 (0.4 to 5.4) 0.63 2 (33%) 3.5 (0.7 to 16.4) 0.16
Troponin elevation 18 (25%) 4 (33%) 1.5 (0.5 to 4.4) 0.48 1 (17%) 0.6 (0.07 to 4.8) 0.99
EKG abnormality 2 (3%) 1 (8%) 3.2 (0.7 to 14) 0.31 0 (0%) - 0.99
ICH 64 (89%) 10 (83%) 0.6 (0.2 to 2.4) 0.61 4 (67%) 0.2 (0.05 to 1.2) 0.14
IVH 54 (75%) 10 (83%) 1.7 (0.4 to 6.9) 0.72 6 (100%) - 0.33
SAH 32 (44%) 7 (58%) 1.7 (0.6 to 5.0) 0.34 3 (50%) 1.2 (0.3 to 5.8) 0.99
Diffuse 14 (19%) 4 (33%) 1 (17%)
Focal 18 (25%) 3 (25%) - 0.40 2 (33%) - 0.85
Absent 40 (56%) 5 (42%) 3 (50%)
BAVM characteristics and treatment
BAVM location
Frontal 25 (35%) 5 (43%) 4 (67%)
Temporal 10 (14%) 0 (0%) 0 (0%)
Parietal 15 (21%) 4 (33%) - 0.31 1 (17%) - 0.77
Occipital 8 (11%) 0 (0%) 0 (0%)
Posterior fossa 14 (19%) 3 (25% 1 (17%)
Size of BAVM*
<3 cm 43 (63%) 7 (58%) 5 (83%)
3 to 6 cm 19 (28%) 3 (25%) - 0.52 0 (0%) - 0.29
>6 cm 6 (8%) 2 (17%) 1 (17%)
Adjacent to eloquent brain * 50 (69%) 7 (58%) 0.5 (0.2 to 1.4) 0.27 3 (50%) 0.4 (0.07; 1.6) 0.32
Deep venous drainage* 31 (43%) 7 (58%) 1.7 (0.5 to 4.7) 0.36 4 (67%) 2.4 (0.5 to 12) 0.40
Co-existing aneurysm*
None 50 (73%) 11 (92%) 5 (83%)
Intranidal 8 (12%) 1 (8%) - 0.99 1 (17%) - 0.99
Feeding vessel 8 (12%) 0 (0%) 0 (0%)
Willis 2 (3%) 0 (0%) 0 (0%)
Surgical resection 35 (49%) 6 (50%) 1.0 (0.3 to 2.8) 0.99 2 (33%) 0.5 (0.1 to 2.5) 0.67
Embolization 15 (20%) 2 (17%) 0.7 (0.2 to 2.9) 0.99 1 (17%) 0.7 (0.1 to 5.6) 0.99
Mixed 6 (8%) 0(0%) to 0.58 0 (0%) - 0.99
Complete treatment 34 (47%) 5 (42%) 1.6 (0.5 to 4.4) 0.53 3 (50%) 1.2 (0.2 to 4.2) 0.99
Early treatment 43 (60%) 8 (67%) 1.4 (0.4 to 4.1) 0.75 3 (50%) 0.7 (0.1 to 3.1) 0.67
ICU outcomes
Norepinephrine 46 (64%) 11 (92%) 6.2 (0.8 to 45) 0.04 6 (100%) - 0.08
Intracranial hypertension 41 (57%) 10 (83%) 3.7 (0.9 to 16) 0.06 6 (100%) 3.8 (0.5 to 31) 0.22
Hypothermia 15 (21%) 4 (33%) 1.9 (0.7 to 5.5) 0.26 3 (50%) 3.8 ( 0.8 to 17) 0.10
CSF drainage 42 (59%) 10 (83%) 3.5 (0.8 to 15) 0.10 6 (100%) - 0.04
ICU LOS 28 (12 to 38) 34 (17 to 41) - 0.09 27 (14 to 36) - 0.74
ICU-free days 6 (0 to 28) 1 (0 to 3) - 0.01 0 (0 to 2) - 0.06
Unfavorable outcome (GOS 1-3) 50 (69%) 11 (92%) 4.9 (0.7 to 35) 0.09 6 (100%) - 0.17
ICU mortality 15 (21%) 5 (42%) 2.7 (1.0 to 7.3) 0.11 3 (50%) 3.8 (0.8 to 17) 0.10
BAVM, brain arteriovenous malformation; CI, cerebral infarction, CSF, cerebrospinal fluid; GCS, Glasgow Coma Scale; ICH, intracerebral hemorrhage; ICU, intensive
care unit; IVH, intraventricular hemorrhage; LOS, length of stay; RR (95%CI), relative risk with the 95% confidence interval; SAH, subarachnoid hemorrhage; TCD-
VS, transcranial Doppler vasospasm. * n = 68 patients (data missing in four patients without vasospasm)
Values are median (IQR) for quantitative variables and N (%) for qualitative variables.
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(odds ratio per unit increase, 0.82; 95% CI, 0.70 to 0.94;
P = 0.01) whereas TCD-VS was not (OR, 2.80; 95%CI,
0.41 to 51; P = 0.36).
Discussion
To the best of our knowledge, this is the first cohort
study describing the incidence and risk factors for cere-
bral vasospasm after BAVM rupture. Although rare
(3.0% of admissions to our ICU), BAVM rupture was
complicated by vasospasm within a few days in 17% of
patients (TCD-VS) or 8% of patients (CI) depending on
the definition used. In our study, the prevalence of cere-
bral vasospasm was lower than in studies of the main
other causes of cerebral vasospasm. TCD-VS was diag-
nosed in 31% to 70% of patients after aneurismal SAH
[4,23] and in 20% to 50% patients with traumatic brain
injury [1,24-26]. We found that time to TCD-VS was 4
to 11 days in 92% of patients (median, 9 days). In the
case-reports of BAVM rupture published over the last
two decades, median time from bleeding to vasospasm
was 13 days [7-13].
Similarly, in a study of 50 patients, angiographic cere-
bral vessel narrowing was noted 3 to 12 days after
BAVM rupture [27]. Furthermore, the time to vasos-
pasm in our study of BAVM rupture was comparable to
that reported after SAH [28] and traumatic brain injury
[1].
We identified three early risk factors for vasospasm:
age, gender, and GCS score. All three factors can be
easily assessed at admission, which may help to stratify
patients presenting with BAVM rupture. Interestingly,
although no previous studies are available for compari-
son, there are eight published case-reports of vasospasm
after BAVM rupture, all in young patients (mean age
was 26 ± 12 years), six of whom are females [7-13]. This
is in accordance with our finding that female gender and
younger age were associated with vasospasm. The third
independent risk factor for vasospasm in our study was
a lower GCS score. Similarly, in previous studies, lower
levels of consciousness predicted vasospasm after SAH
[29] and traumatic brain injury [1]. In the present study,
intraventricular hemorrhage was present in 83% and
100% of the patients with TCD-VS and CI, respectively,
in accordance with the occurrence of IVH in all eight
previously reported cases of vasospasm following BAVM
rupture. The amount of blood in the subarachnoid
spaces as assessed by the Fisher score has been recog-
nized as a strong predictor of cerebral vasospasm after
SAH [5]. However, the Fisher score did not significantly
predict cerebral vasospasm in our study, and vasospasm
has been reported after BAVM rupture without SAH
[7,8,10,13]. Although the exact pathophysiology of cere-
bral vasospasm remains unknown, our data and pre-
viously published cases suggest that IVH, but not SAH,
may be associated with the development of vasospasm
after BAVM rupture. Experimental evidence suggests
that oxyhemoglobin release secondary to blood clot
elimination may initiate the cascade involving vasoactive
substances such as endothelium-derived nitrite oxide
and endothelin-1, which leads to cerebral vasospasm
[30,31]. Further research is needed to clarify the patho-
physiology of vasospasm after BAVM rupture and to
explain the different impacts of subarachnoid and intra-
ventricular clots on the genesis of vasospasm. Due to
the small number of patients included in the present
study, we were not able to identify additional predictors,
although we found a trend toward an association
between angio-architectural BAVM features and cerebral
vasospasm. The high proportion of patients who
received norepinephrine in the TCD-VS and CI groups
compared to the group without vasospasm is ascribable
Figure 1 Flow chart of the study patients. BAVM, brain arteriovenous malformation; ICU, intensive care unit.
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tion in patients diagnosed with vasospasm, as part of
“triple-H” therapy.
Although evidence is lacking that treatments such as
triple-H therapy, transluminal balloon angioplasty, or
selective intraarterial vasodilator infusion are effective in
SAH patients, these strategies are commonly used in
this group of patients. Based on the current data it
would be worthwhile to investigate the efficacy of these
treatments in patients with ruptured BAVMs. No clear
recommendations about arterial blood pressure manage-
ment after BAVM treatment are available. Hyperemia
has been documented after BAVM treatment. Although
the underlying mechanism seems unrelated to systemic
hemodynamic changes [32], induced moderate hyperten-
sion may cause cerebral and systemic complications.
Nevertheless, preventive strategies, such as nimodipine,
might deserve evaluation in patients with BAVM rup-
ture who are at high risk for vasospasm.
CI has been identified as the only outcome predictor
in patients with SAH [4]. In the present study, TCD-VS
and CI were associated with a non-significant increase
in the risk of poor outcomes. Although the 21% death
rate found in our study is close to the 18% 30-day rate
reported by Brown et al. [33], it was lower than the 29%
rate found by the same group in patients with previously
untreated BAVM [34]. Nevertheless, the Colombia
group found a lower mortality rate [35] and another
study found no mortality at all [36]. Furthermore, in a
defined-population study, the case-fatality rate in
patients younger than 60 years was about 10% [37]. The
comparatively high mortality rate in our patients may be
ascribable to differences in severity at admission. In our
series, all the patients required ICU admission and 40%
were comatose. Since no high-level evidence exists con-
cerning the management of unruptured BAVM, hetero-
geneity in the treatment methods may contribute to
explain mortality rate differences across studies. The
ongoing Randomized Trial of Unruptured Brain Arterio-
venous Malformations (ARUBA) [38] comparing treat-
ment versus conservative management of unruptured
BAVM can be expected to provide answers on this last
point.
Unfortunately, the number of patients included was
too small to determine whether TCD-VS and CI were
independently associated with a poor outcome. Several
definitions of cerebral vasospasm are commonly used,
including TCD velocity elevation above 120 cm/s,
Figure 2 Cerebral digital subtraction angiography in a patient
with vasospasm after rupture of a BAVM. Cerebral digital
subtraction angiography performed 11 days after intraventricular
hemorrhage in a 33-year-old patient with two brain arteriovenous
malformations (BAVMs): a ruptured BAVM in the right frontal lobe
and an intact BAVM in the left temporal lobe. Right internal carotid
artery (ICA) injection, anteroposterior (AP) (A) and lateral (B) views:
severe vasospasm of the M1 segment of the right middle cerebral
artery (black arrow) and terminal right internal carotid artery (black
arrowhead). Small frontal BAVM (double white arrow). Left ICA
injection, AP view (C): severe vasospasm of the M1 segment (black
arrow). The other BAVM is visible in the temporal lobe (triple white
arrow). Cerebral CT scan (D): vasospasm-associated cerebral
infarction in both the left middle and the left anterior cerebral
arteries (**). Note the remnant of the intraventricular hemorrhage
(white arrow).
Figure 3 Cumulative incidence of transcranial Doppler
vasospasm in patients with ruptured brain arteriovenous
malformations.
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Page 6 of 10Table 2 Cases of cerebral vasospasm after rupture of a BAVM, adapted from Yanaka et al. [3] and Gerard et al.[ 7 ]
Clinical and radiological
features
BAVM angioarchitectural features BAVM treatment Vasospasm features and management Outcome
# Sex GCS SAH IVH ICH Location Venous
drainage
Size
(mm)
Eloquence Spetzler
Martin
Grade
Co-
existing
aneurism
BAVM
treatment
Exclusion Time to
treatment
Time to
onset
(days)
TCD Mean
flow
velocity
(cm/s)
TCD-VS
artery
CI
location
Medical
treatment
Endovascular
treatment
GOS Causes of
death
1 M 4 A Y N R. frontal Superf. <30 N 1 N None - - 11 200 B MCA L ACA L
MCA
Nimodipine IA Nimodipine 1 Cerebral
ischemia
2F 3 F Y Y R .
temporal
Superf. 30 to
60
N 2 N Surgery Total <24 h 9 160 B MCA None None 2 -
3 M 3 F Y Y R. frontal Deep >60 Y 5 N None - - 10 150 B MCA R MCA
R ACA L
MCA
None None 1 Intracranial
hypertension
4 F 3 D Y Y Cerebellum Superf. <30 Y 2 N Surgery Total <24 h 6 169 B MCA
R ACA L
VA, BA
None None 1 Intracranial
hypertension
5 M 10 A N Y Cerebellum Superf. <30 Y 2 N Surgery Total <24 h 4 150 B MCA
B ACA
Nimodipine None 2 -
6 M 4 D Y Y R. parietal Deep 30 to
60
N 3 N Surgery Total <24 h 7 222 L MCA Nimodipine IA Nimodipine
IA Milrinone
1 Initial bleed
7 F 7 A Y Y L. parietal Deep <30 N 2 Intranidal None - - 13 165 B MCA R MCA Nimodipine None 3 -
8 F 7 F Y Y Posterior
cranial
fossa
Superf. <30 N 1 N Surgery Total <24 h 11 162 B MCA B MCA
B PCA
None IA Nimodipine
IA Milrinone
1 Cerebral
ischemia
9 F 13 D Y N L. frontal Deep <30 Y 3 N Embolization Total 5 d 9 160 R MCA R MCA
RACA
Nimodipine IA Nimodipine
IA Milrinone
2-
10 F 5 A Y Y R. frontal Deep <30 Y 3 N Surgery Total <24 h 4 194 B MCA
R ACA
L MCA Nimodipine None 3 -
11 F 3 D Y Y R. frontal Deep >60 Y 5 N Embolization Incom-
plete
<24 h 11 185 B MCA
B ACA
Nimodipine None 5 -
12 M 8 A N Y R. parietal Deep 30 to
60
Y 4 N None - - 4 217 R MCA Nimodipine None 3 -
A, absent; ACA, anterior cerebral artery; B, bilateral; BA, basilar artery; BAVM, brain arteriovenous malformation; CI, cerebral infarction; D, diffuse; F, focal; GCS, Glasgow Coma Scale; GOS, Glasgow Outcome Scale; IA,
intraarterial; ICA, internal carotid artery; ICH, intracerebral hemorrhage; IVH, intraventricular hemorrhage; L, left; MCA, middle cerebral artery; N, no; PCA, posterior cerebral artery; R, right; SAH, subarachnoid
hemorrhage; Superf, superficial; TCD, transcranial Doppler; TCD-VS, vasospasm detected using transcranial Doppler; VA, vertebral artery; Y, yes.
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CI diagnosed by CT or MRI. TCD is a well-validated
tool for detecting vasospasm [39,40] with acceptable
positive and negative predictive values for angiographic
vasospasm but low sensitivity for predicting the neurolo-
gical outcome [41]. Moreover, intra- and inter-observer
variability is of concern and should be taken into
account when interpreting velocity changes over time.
Nevertheless, intra-observer bias may be minimized by
having the same neurointensivist perform all TCD
investigations in a given patient [42], as was the case in
the present study. Furthermore, mean flow velocities
were well above 120 cm/s, and using a higher cut-off
point of 150 cm/s would not have changed our results.
In our study, TCD was performed in unconscious
patients and in awake patients with symptoms. Since
not all patients with vasospasm have symptoms, this
approach may have underestimated the true incidence
of TCD-VS. Angiographic vasospasm was not consid-
ered in our study. The absence of recommendations
about vasospasm management after BAVM rupture and
the poor clinical condition ofs o m ep a t i e n t sp r e c l u d i n g
transport to the radiology department explain that DSA
was not performed routinely. This weakness of our
study is mitigated by the good reported correlation
between TCD and DSA [39] for vasospasm assessment.
Furthermore, DSA may require general anesthesia and is
associated with a small risk of procedure-related stroke.
Finally, no treatment recommendations are available for
BAVM rupture with vasospasm. Conceivably, the local
cerebral blood flow modifications induced by intra-
arterial treatments may lead to re-bleeding, especially
when the BAVM has not been secured.
There are several limitations to our study. First, we
used a retrospective design in a small number of
patients from a single center. However, given the preva-
l e n c eo fB A V Mo fo n l ya b o u t0 . 0 1 %i nt h eg e n e r a l
population [43], a retrospective design was appealing to
ensure study completion within a reasonable timeframe.
Second, our data from a single center may not apply to
all other centers. Third, vasospasm following BAVM
rupture is rare and, consequently, our sample size was
small, limiting the statistical power of our study, which
may have led us to miss a number of risk factors. More-
over, the number of patients included in the present
study was too small to investigate properly whether
TCD-VS and CI were independent predictors of a poor
outcome. This crucial point will have to be determined
in a larger study. In addition, the number of patients
with CI was also too small for a separate multivariate
analysis of risk factors for this event.
Conclusions
After BAVM rupture, TCD-VS occurred in 17% of
patients and CI in 8%. Admission risk factors for TCD-
VS were low GCS, younger age, and female gender. A
non-significant trend toward poorer outcome exists in
patients with TDC-VS and CI. Prospective, multicenter
studies are needed to further assess the incidence and
significance of vasospasm and CI after BAVM rupture
and to identify additional predictors.
Key messages
￿ Transcranial Doppler cerebral vasospasm is a com-
mon complication following brain arteriovenous
rupture.
￿ Cerebral vasospasm in brain arteriovenous rupture
is associated with low GCS, young age, and female
gender.
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